BACKGROUND: In this study, the authors examined the influence of prior treatment on the course of fatigue in breast cancer survivors. Patients who received chemotherapy were expected to have greater fatigue than patients who received radiotherapy and noncancer controls 6 months after the completion of treatment, but they were expected to recover to levels similar to those of the other 2 groups 3 years later. METHODS: Patients with stage 0 through II breast cancer completed the Fatigue Symptom Inventory (FSI) and the Profile of Mood States Fatigue Scale (POMS-FAT) 6 months (T1) and 42 months (T2) after completing chemotherapy with or without radiotherapy (the CT group; n = 103) or radiotherapy only (the RT group; n = 102). An age-matched group of women with no history of cancer (the NC group; n = 193) was assessed over a similar interval. RESULTS: A significant (P = .041) group × time effect for FSI severity scores revealed that fatigue worsened over time in the CT group but remained stable and lower in the RT and NC groups. There also were significant group effects for FSI days (P < .001) and POMS-FAT (P = .010) scores, indicating that fatigue was significantly greater across time in the CT group than in the NC group (POMS-FAT) or the RT and NC groups (FSI days). CONCLUSIONS: Contrary to expectations, fatigue did not diminish over time in patients with breast cancer who received chemotherapy. This finding has important implications for patient education and for fatigue monitoring during follow-up. The authors concluded that future research should seek to examine possible mechanisms to explain the apparent prolonged impact of chemotherapy on fatigue in breast cancer survivors.
BACKGROUND: In this study, the authors examined the influence of prior treatment on the course of fatigue in breast cancer survivors. Patients who received chemotherapy were expected to have greater fatigue than patients who received radiotherapy and noncancer controls 6 months after the completion of treatment, but they were expected to recover to levels similar to those of the other 2 groups 3 years later. METHODS:Patients with stage 0 through II breast cancer completed the Fatigue Symptom Inventory (FSI) and the Profile of Mood States Fatigue Scale (POMS-FAT) 6 months (T1) and 42 months (T2) after completing chemotherapy with or without radiotherapy (the CT group; n = 103) or radiotherapy only (the RT group; n = 102). An age-matched group of women with no history of cancer (the NC group; n = 193) was assessed over a similar interval. RESULTS: A significant (P = .041) group × time effect for FSI severity scores revealed that fatigue worsened over time in the CT group but remained stable and lower in the RT and NC groups. There also were significant group effects for FSI days (P < .001) and POMS-FAT (P = .010) scores, indicating that fatigue was significantly greater across time in the CT group than in the NC group (POMS-FAT) or the RT and NC groups (FSI days). CONCLUSIONS: Contrary to expectations, fatigue did not diminish over time in patients with breast cancer who received chemotherapy. This finding has important implications for patient education and for fatigue monitoring during follow-up. The authors concluded that future research should seek to examine possible mechanisms to explain the apparent prolonged impact of chemotherapy on fatigue in breast cancer survivors.
Authors: P J Goodwin; M Ennis; K I Pritchard; D McCready; J Koo; S Sidlofsky; M Trudeau; N Hood; S Redwood Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Hans Geinitz; Frank B Zimmermann; Reinhard Thamm; Monika Keller; Raymonde Busch; Michael Molls Journal: J Cancer Res Clin Oncol Date: 2004-03-06 Impact factor: 4.553
Authors: D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman Journal: Qual Life Res Date: 1998-05 Impact factor: 4.147
Authors: D Howell; S Keller-Olaman; T K Oliver; T F Hack; L Broadfield; K Biggs; J Chung; D Gravelle; E Green; M Hamel; T Harth; P Johnston; D McLeod; N Swinton; A Syme; K Olson Journal: Curr Oncol Date: 2013-06 Impact factor: 3.677
Authors: Fay Wright; Gail D'Eramo Melkus; Marilyn Hammer; Brian L Schmidt; M Tish Knobf; Steven M Paul; Frances Cartwright; Judy Mastick; Bruce A Cooper; Lee-May Chen; Michelle Melisko; Jon D Levine; Kord Kober; Bradley E Aouizerat; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2015-03-28 Impact factor: 3.612
Authors: Olga Husson; Floortje Mols; Lonneke van de Poll-Franse; Jolanda de Vries; Goof Schep; Melissa S Y Thong Journal: Support Care Cancer Date: 2015-01-06 Impact factor: 3.603
Authors: Kristin M Phillips; Heather L McGinty; Brian D Gonzalez; Heather S L Jim; Brent J Small; Susan Minton; Michael A Andrykowski; Paul B Jacobsen Journal: Psychooncology Date: 2012-03-15 Impact factor: 3.894
Authors: J L Vardy; H M Dhillon; G R Pond; C Renton; A Dodd; H Zhang; S J Clarke; I F Tannock Journal: Ann Oncol Date: 2016-07-20 Impact factor: 32.976
Authors: Melissa S Y Thong; Floortje Mols; Lonneke V van de Poll-Franse; Mirjam A G Sprangers; Carin C D van der Rijt; Andrea M Barsevick; Hans Knoop; Olga Husson Journal: J Cancer Surviv Date: 2017-09-09 Impact factor: 4.442
Authors: Heather S L Jim; Aasha I Hoogland; Hyo Sook Han; Eva Culakova; Charles Heckler; Michelle Janelsins; Geoffrey C Williams; Julienne Bower; Stephen Cole; Zeruesenay Desta; Margarita Bobonis Babilonia; Gary Morrow; Luke Peppone Journal: Contemp Clin Trials Date: 2020-03-05 Impact factor: 2.226